AOD 9604 5 mg by Dragon Pharma is a synthetic peptide fragment modeled after human growth hormone (HGH), specifically the lipolytic region responsible for fat breakdown. While it does not induce anabolic effects like full-length HGH, it retains the ability to activate beta-adrenergic lipolytic pathways. This makes it an ideal candidate for research in obesity, metabolic regulation, and adipose tissue remodeling.
Mechanism of Action
AOD 9604 is derived from amino acids 176–191 of the growth hormone molecule. This truncated sequence is believed to enhance fat degradation by stimulating lipolysis and inhibiting lipogenesis, without elevating blood sugar or triggering insulin resistance. Studies suggest it activates enzymes such as hormone-sensitive lipase (HSL), facilitating the release of stored fatty acids into circulation.
Unlike growth hormone, AOD 9604 does not promote IGF-1 release, making it attractive for metabolic-focused research without the muscular hypertrophy or endocrine feedback complications associated with GH analogs. It has also been explored for joint repair, cartilage regeneration, and general metabolic recovery in murine and primate studies.
Key Features & Benefits
- Targeted Fat Metabolism: Studied for its ability to enhance lipolysis without influencing muscle growth pathways.
- Low IGF-1 Interaction: Does not stimulate insulin-like growth factor, supporting clean metabolic targeting in experiments.
- Supports Obesity Research: Investigated for weight loss models and adipose-related disorders in preclinical settings.
- Joint & Cartilage Benefits: Secondary studies suggest regenerative support for cartilage and soft tissues.
- Precision Formulation: Manufactured by Dragon Pharma for high-purity injectable peptide research.
Legal Disclaimer
Disclaimer: AOD 9604 is supplied strictly for laboratory use and preclinical experimentation. It is not approved for medical, diagnostic, or human application. Use only in certified research environments by trained professionals.
Frequently Asked Questions
In controlled studies, AOD 9604 has shown promising fat reduction effects through enhanced lipolysis without affecting lean muscle mass or IGF-1 levels.
AOD 9604 has shown a favorable safety profile in research, with minimal systemic side effects due to its selective action. However, full toxicological data is still under review.
Weight reduction depends on study duration, species, and dose. In murine models, significant fat mass decrease was observed without changes in food intake or lean mass.
